

07-15-2004 09:24AM FROM-Gates & Cooper LLP

+13106418798

T-858 P.017/029 F-991

**ATTACHMENT B**

MAY 5, 1997  
VOLUME 102 (5A)

# The American Journal of Medicine.


## PERSPECTIVES ON HUMAN PAPILLOMAVIRUS INFECTION

### GUEST EDITOR

Stephen Tyring, MD, PhD


Departments of Dermatology, Microbiology and Immunology,  
and Internal Medicine

University of Texas Medical Branch  
Galveston, Texas



VETERINARY LIBRARY  
ST. PAUL CAMPUS

OFFICIAL JOURNAL OF



EXCERPTA MEDICA, INC.

PAGE 18/29 \* RCVD AT 7/15/2004 1:11:43 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-1/5 \* DNIS:8729306 \* CSID:+13106418798 \* DURATION (mm:ss):10:32

MAY 5, 1997  
VOLUME 102 (5A)

# The American Journal of Medicine.

## PERSPECTIVES ON HUMAN PAPILLOMAVIRUS INFECTION

### GUEST EDITOR

**Stephen Tyring, MD, PhD**

Departments of Dermatology, Microbiology and Immunology,  
and Internal Medicine  
University of Texas Medical Branch  
Galveston, Texas

The publication of this supplement is made possible by an unrestricted educational grant from 3M Pharmaceuticals, St. Paul, Minnesota.

**Senior Editor David Good**  
**Production Editor Craig Smith**

**Associate Publisher David Dionne**  
**Proof Editor Mary Crowell**

### THE AMERICAN JOURNAL OF MEDICINE®

**Publisher:** The American Journal of Medicine® (ISSN 0002-9343, GST #122397487) is published four times in May, two times in January, February, March, and April, and one time in June, July, August, September, October, November, and December, by Excerpta Medica, Inc., 245 West 17th Street, New York, NY 10011. Telephone (212) 482-9933, FAX (212) 482-1935.

**Copyright:** Copyright © 1997 by Excerpta Medica, Inc. All rights reserved. This journal and the individual contributions contained in it are protected by the copyright of Excerpta Medica, Inc. and the following terms and conditions apply to their use:

**Photocopying:** Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. In the USA, users may clear permissions and make payment through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923; telephone (508) 750-8400. In the UK, users may clear permissions and make payment through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 96 Leonard Street, London EC2A 3RH; telephone (0171) 631-8080.

**Derivative Works:** Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations.

**Electronic Storage:** Permission of the publisher is required to store electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated.

**Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.**

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, independent verification of diagnoses and drug dosages should be made.

**Reprint Inquiries:** Should be addressed to Dan Cronin, Excerpta Medica, Inc., Madison Square Station, P.O. Box 882, New York, NY 10159-0882. Telephone (212) 633-2043. Fax (212) 633-2043.

**Subscription:** Solicited only from internists and other physicians. Publisher reserves the right to refuse unqualified subscribers. Please address all subscription mail to The American Journal of Medicine®, Excerpta Medica, Inc., P.O. Box 10567, Riverton, NJ 08076-0567. Telephone (212) 989-5900. Single copy price: Regular issues \$12; symposia and special issues \$27. Subscription rates: U.S. 1 year \$69, 2 years \$121, 3 years \$172. All other countries (prices include air-speeded delivery) 1 year \$179, 2 years \$313, 3 years \$448. Institutions: U.S. 1 year \$149; all other countries (prices include air-speeded delivery) 1 year \$259. Publisher is not responsible for replacing missing issues unless the Circulation Department is notified of nonreceipt within 3 months of issue date for domestic addresses and 6 months for foreign addresses. Circulation records are maintained at Excerpta Medica, Inc., Madison Square Station, P.O. Box 882, New York, NY 10159-0882.

**Send address changes to:** The American Journal of Medicine®, Excerpta Medica, Inc., P.O. Box 10567, Riverton, NJ 08076-0567. Please include a copy of the old address label. Changes of address must reach the Journal 1 month preceding month of issue.

**Postmaster:** Send address changes to The American Journal of Medicine®, Excerpta Medica, Inc., P.O. Box 10567, Riverton, NJ 08076-0567. Periodicals postage paid at New York, NY and additional mailing offices.

## Therapeutic Approaches to Genital Warts

Karl R. Beutner, MD, PhD, San Francisco, California, Alex Ferenczy, MD, Montreal, Quebec, Canada

Although many treatments are available for genital warts caused by human papillomavirus (HPV), none are uniformly successful in the treatment of this disease. Most current treatment options work by destroying affected tissue, either by a cytotoxic or a physically ablative mode of action. Interferons have antiviral, antiproliferative, and immunomodulatory activities, but these have not translated into a high level of cure rates against warts. With all current treatments, recurrent warts are common. Therapies currently being investigated include a 5-fluorouracil/epinephrine collagen gel that achieves high concentrations of 5-fluorouracil at the site of injection. Other new treatment modalities focus on activating the host's immune system or improving the delivery of therapeutic compounds to the affected site. Imiquimod, a novel immune-response modifier, induces interferon and a number of other endogenous cytokines. A cream formulation containing 5% imiquimod resulted in good total clearance rates and generally tolerable side effects in controlled clinical trials of patients with external genital warts. Perhaps the most effective means for managing HPV disease would be a vaccine that prevents the occurrence of genital warts. Although it is unlikely that such a vaccine will be introduced in the near future, preliminary studies indicate that it may be possible to develop suitable prophylactic and therapeutic vaccines. *Am J Med.* 1997;102(5A):28-37. © 1997 by Excerpta Medica, Inc.

There are no simple, routinely effective therapies available for the treatment of genital warts, a disease caused by human papillomavirus (HPV). The lack of such therapy often makes the treatment of genital warts a frustrating experience for both the patient and the clinician.

For many diseases, there is little question as to whether offering treatment to a patient is appropriate. Therapy for genital warts is more problematic, however, as some of the recognized goals for treating bacterial sexually transmitted diseases are not necessarily accomplished by treatment of genital warts.<sup>1</sup> Current therapies have a low effectiveness in preventing wart recurrence, and there is little evidence that treatment reduces the likelihood of disease transmission. In many cases, the best that can be hoped for is a temporary reduction of symptoms.

Nevertheless, because genital HPV infections are cosmetically unacceptable and may be associated with discomfort and physical and psychosocial dysfunction, treatment is generally offered to all patients with genital lesions. Other rationales for treatment include the amelioration of symptoms, particularly during wart-free periods, and the possibility of decreased infectivity, not only of HPV, but of other blood-borne infections whose transmission may be enhanced by friable genital warts. Furthermore, in very rare instances, HPV types normally found in genital warts are capable of producing verrucous squamous cell carcinoma (e.g., giant condyloma of Buschke-Löwenstein).

Although experience indicates that most of the current therapies eventually remove warts, recurrences are common. Recurrent warts may be caused by activation of latent virus present in normal skin adjacent to the lesions.<sup>2</sup> New therapies are attempting to improve the efficacy of current treatments by stimulating the host's immune system to eradicate viral infection or by enhancing delivery of therapeutic compounds to HPV-associated lesions.

This article reviews the treatment options available for patients with genital warts, with a focus on new therapies for this disease. These investigational therapies may soon expand the options currently available for the treatment of genital warts.

### CURRENT THERAPIES FOR GENITAL WARTS

Many of the therapies used to treat genital warts have been available for decades. In many cases, the

From the Department of Dermatology, University of California at San Francisco, San Francisco, California; and the Departments of Pathology and Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada.

Requests for reprints should be addressed to Karl R. Beutner, MD, PhD, Solano Dermatology, 127 Hospital Drive, Vallejo, CA 94585.

## A SYMPOSIUM: HUMAN PAPILLOMAVIRUS INFECTION/BEUTNER AND FERENCZY

TABLE I

Summary of Selected Published Data on Cytotoxic and Physically Ablative Therapies for Human Papillomavirus Infection

Treatment	Average No. of Treatments (range)*	Success Rates (range)*	Recurrence Rates (range)*	References
<b>Cytotoxic agents</b>				
Trichloroacetic acid (Tri-Chlor)	4.0	64-81%	36%	[3, 4]
Podophyllin (Pod-Ben-25, Podocon-25, Podofin)	3.4-6.7	38-79%	21-65%	[7-14]
Podoflox (Candylox)	3.2 treatment cycles (patient applied)	68-88%	16-34%	[12, 14, 18, 19]
5-FU (Efudex, Fluoroplex)	2-2.5 treatment cycles (patient applied)	68-97%	0-8%	[20, 21]
<b>Physically ablative therapies</b>				
Cryotherapy	2.6-3.2	70-96%	25-39%	[3, 4, 7, 11, 26]
CO <sub>2</sub> laser	1.0-2.0	72-97%	6-49%	[21, 28-31]
Electrodesiccation	1.3	94%	25%	[11]
LEEP	NR	72%	51%	[31]
Surgical excision	1.1	89-93%	19-22%	[10, 13]

5-FU = 5-fluorouracil; LEEP = loop electrosurgical excisional procedure; NR = not reported.

\*Ranges are reported where possible; not all papers reported data on all of the parameters included in this table.

safety and effectiveness of these treatments have not been assessed in well-controlled, prospective clinical trials. Comparative trials of therapies are also relatively rare. The dearth of such information can make it difficult to evaluate the efficacy of different treatment modalities.

Table I summarizes selected published data on current genital wart therapies. It should be noted that a number of factors can influence the figures presented in this table. In particular, the location and extent of genital warts, the sex of the patients studied, the treatment regimen, and the quality of care can all be important factors in the success of therapy. Both success and recurrence rates are also heavily affected by the time of assessment; in studies with low recurrence rates, patients may simply have been examined for a shorter time period than in studies with high recurrence rates. All of these factors should be kept in mind when evaluating different studies and therapies.

### Cytotoxic Agents

Cytotoxic therapies eliminate genital warts by destroying the affected tissue, either through chemodestructive or antiproliferative modes of action. The therapies described in this section are all applied topically. Unlike surgical procedures, cytotoxic therapies do not generally require local anesthesia. Nevertheless, cytotoxic agents are not painless; local skin reactions are common and in some cases can be severe. The relative merits of various cytotoxic agents are shown in Table I.

### Trichloroacetic Acid

Trichloroacetic acid (TCA; trade name, Tri-Chlor) is a chemodestructive agent that causes chemical co-

agulation of genital warts. An 80-90% solution of TCA is applied directly to the genital wart in the clinic or the physician's office. This treatment can be repeated weekly if necessary. Although TCA has little systemic toxicity, lack of control over the depth of penetration and breadth of the treatment area may result in discomfort and, in rare cases, ulcers and scarring.<sup>3</sup> TCA is effective in the initial destruction of external genital warts and works best when used to treat small, moist warts. As TCA is not absorbed in the general circulation, this compound can be used to treat pregnant patients. However, early recurrences may be frequent. In one study, 36% of treated patients had new lesions within 2 months.<sup>4</sup>

### Podophyllin

Podophyllin, a plant compound that causes tissue necrosis by arresting cells in mitosis, is frequently used in the treatment of external genital warts. Podophyllin is applied to warts at concentrations of 10-25% in compound tincture of benzoin. After 1-4 hours, the compound should be thoroughly washed off. Podophyllin is usually applied once weekly for up to 6 weeks.

Current recommendations advise that podophyllin application be limited to <0.5 mL or <10 cm<sup>2</sup> per session to decrease the potential for systemic effects, including bone marrow depression. The systemic toxicity of podophyllin precludes its use during pregnancy.<sup>5</sup> In addition, recent studies have indicated that podophyllin resin may contain mutagenic substances.<sup>6</sup> Podophyllin treatment causes local skin reactions, including redness, tenderness, itching, burning, pain, and swelling.

Approximately 50% of patients respond to treatment, but warts recur in about 40% of them.<sup>7-14</sup> Be-

**A SYMPOSIUM: HUMAN PAPILLOMAVIRUS INFECTION/BEUTNER AND FERENCZY**

cause podophyllin is not a standardized compound, the efficacy of different batches may vary significantly.<sup>18,19</sup> In addition, podophyllin is ineffective on relatively dry anogenital areas, including the penile shaft, scrotum, and labia majora.<sup>18</sup>

**Podofilox**

Podofilox (also known as podophyllotoxin), the major biologically active lignan of podophyllin resin, is available by prescription as a 0.5% solution for self-application to external genital warts. Treatment of genital warts with podofilox solution involves twice-daily application with a cotton swab for 3 days, followed by 4 days without treatment. This cycle can be repeated 4–6 times as necessary. It is recommended that treatment with podofilox be limited to a wart area of  $\leq 10 \text{ cm}^2$ . Pregnant women should not use podofilox.<sup>6</sup>

Podofilox has several advantages over podophyllin, including a standardized formulation and self-administration by the patient. In addition, podofilox has a lower degree of systemic absorption than podophyllin.<sup>17</sup> Comparative studies indicate that podofilox is more effective and results in faster resolution of warts than podophyllin.<sup>12,14</sup> However, as with podophyllin, recurrent warts are common following podofilox treatment. Recurrences occur in approximately one third of previously resolved warts during the first month after treatment.<sup>18,19</sup>

**5-Fluorouracil**

The antimetabolite 5-fluorouracil (5-FU) inhibits cell growth by interfering with DNA and RNA synthesis. Topical treatment with 5% 5-FU cream can be helpful in the treatment of some forms of genital warts. In the small studies that have been conducted, about 75% of patients experienced clearance of warts; recurrence rates of <10% have been reported.<sup>20,21</sup>

Although topical treatment with 5-FU does not appear to result in significant systemic toxicity,<sup>20</sup> because it is a teratogen its use is contraindicated during pregnancy. The major drawback of 5-FU therapy is a high level of local irritation. Because of this effect, some patients are unable to tolerate treatment.<sup>22</sup> Vaginal ulcerations and one report of vaginal adenosis with clear cell carcinoma have prompted some clinicians to avoid using 5-FU for the treatment of vaginal condylomata.<sup>23,24</sup> However, this agent may be useful for the treatment of vulvar, perianal, penile, and meatal warts. A thin layer of cream is usually spread over freshly cleaned lesions 1–3 times per week. Depending on the sensitivity of the location, the cream should be washed off after 3–10 hours. Applications may continue for several weeks as needed. Because of the possibility of periconceptual

fetal toxicity, the patient should be protected from pregnancy, preferably by oral contraceptives, during 5-FU therapy.<sup>25</sup>

**Physically Ablative Therapies**

There are a number of physically ablative procedures that have been used to destroy genital warts. Although these techniques often achieve reasonable initial success rates, recurrence rates can also be high (Table I). In addition, physically ablative therapies are painful, and anesthesia is usually required.

**Cryotherapy**

Cryotherapy, usually with liquid nitrogen as the cryogen, can be used to treat genital and anal warts in patients who do not have extensive disease. Cryotherapy results in the freezing and destruction of the wart and a small area of surrounding tissue.

Cryotherapy clears warts in approximately 75% of patients.<sup>3,4,7,11,26</sup> One comparative study found that cryotherapy was more effective than podophyllin in the treatment of condylomata acuminata, resulting in the elimination of genital warts in 79% of patients treated with cryotherapy, compared with 51% in the podophyllin-treated group. At 6 weeks' follow-up, warts recurred in 21% (30/144) of patients.<sup>7</sup>

In cryotherapy, a cryoprobe,<sup>27</sup> modified Q-tip, or fine spray is used to apply liquid nitrogen to the wart. Freezing is usually continued until a frozen area slightly larger (1–2 mm) than the diameter of the wart is formed. This procedure can be repeated at 1- or 2-week intervals; typically, only two or three sessions are required.

Cryotherapy can be painful, but this effect can usually be managed by the use of a local anesthetic. Because there are no systemic effects, cryotherapy can be used to treat genital warts in pregnant women.<sup>27</sup>

**Laser Therapy**

Properly performed CO<sub>2</sub> laser treatment has achieved excellent results in the treatment of genital warts.<sup>21,28–31</sup> Recurrence rates vary from low (6–17%)<sup>21,28–30</sup> to high (49%).<sup>31</sup> Laser therapy has been successful in the treatment of penile, anorectal, and urethral warts in men<sup>30</sup> and flat warts of the vagina in women.<sup>31</sup> Laser treatment is also a popular choice for the treatment of lesions that have not responded to other therapies and for extensive HPV disease, because the precision of this technique allows normal adjacent tissue to be spared. As with cryotherapy, there are no systemic effects with laser therapy, so it may be safely performed during pregnancy.<sup>32</sup>

The major drawbacks of laser therapy are the special training and expensive equipment required for treatment. Anti-infective measures must be closely

**A SYMPOSIUM: HUMAN PAPILLOMAVIRUS INFECTION/BEUTNER AND PERENCZY**

followed during laser therapy. It is essential that a fume evacuator be used to prevent the inhalation of allergens and HPV DNA found in laser plumes.<sup>33</sup> It is not yet known whether HPV DNA spread by laser energy onto treatment fields and the surrounding normal tissue causes recurrent disease.<sup>34</sup>

Because the procedure is associated with extreme heat, local or general anesthesia is required for laser treatment. In unskilled hands, severe thermal damage to underlying tissue can occur. Side effects include pain, itching, and swelling.

**Electrosurgery**

Electrosurgical methods use high frequency current to destroy (fulgurate) tissue affected by genital warts. In many cases, local anesthesia is sufficient for patients undergoing this procedure.

**Electrodesiccation.** Although electrodesiccation is commonly used in the treatment of genital warts, few studies on this technique have been published. In one comparative study, electrodesiccation was found to result in a higher rate of complete wart clearance than podophyllin or cryotherapy (94% vs 41% and 79%, respectively).<sup>11</sup> All three treatment groups were found to have similar recurrence rates in the same range. Another advantage of electrodesiccation was the number of treatments required, a mean of 1.3 compared with >3 for the other two therapies.

**Loop electrosurgical excisional procedure.** Loop electrosurgical excisional procedure (LEEP) combines electroexcision and fulguration. In many clinics, it has replaced traditional electrosurgical techniques in the treatment of cervical intraepithelial neoplasia (CIN)<sup>35</sup> and external condylomata.<sup>31</sup> In the latter case, the lesion is elevated by a local anesthetic solution or saline (if the patient is treated under general anesthesia), and a small loop electrode is inserted into the superficial dermis (Figure 1).<sup>36</sup> This technique works best with larger, pointed warts; smaller, papular lesions are best treated by electrodesiccation.

A comparative study in >200 male and female patients found that the efficacy and adverse effects of LEEP are similar to those associated with laser ablation in the treatment of external condylomata.<sup>31</sup> Furthermore, LEEP resulted in less blood loss and a shorter operating time than did laser ablation or cold knife conization.<sup>37</sup>

Local anesthesia is typically given to patients with localized lesions, whereas those with extensive disease require general anesthesia. The most common side effect of LEEP for external anogenital condylomata is perioperative bleeding. If the loop electrode penetrates deep into the dermis, bleeding and scarring may result. Because scarring of the penis

can result in dysfunction, most physicians prefer CO<sub>2</sub> laser vaporization or cryotherapy over LEEP for penile warts. Infections occur infrequently and can usually be controlled by antibiotics.

**Surgical Excision**

Surgical tangential excision using either cold knife or scissors has a high success rate in the treatment of genital warts, resulting in approximately 90% wart clearance rates and about 20% recurrence rates.<sup>10,12</sup> Although this technique is often reserved for extensive disease or refractory cases, surgical excision is also successful in the treatment of isolated warts. Compared with other physically ablative methods, surgical excision by a skilled physician is associated with good healing and less pain.

**Interferons**

Interferon (IFN) is an attractive candidate for the treatment of warts because it has immunomodulatory and antiproliferative effects as well as antiviral activity. Despite its antiviral effects, however, there is evidence that IFN therapy does not eradicate viral infection.<sup>38</sup>

To date, only IFN- $\alpha$ , the form of IFN produced by virus-infected leukocytes or lymphoblasts, is approved for intralesional use in the treatment of genital warts. Accordingly, most studies have been conducted with either natural or recombinant IFN- $\alpha$ . Various routes of IFN administration, including intralesional, topical, and parenteral, have been assessed in patients with genital warts (Table II).

**Intralesional Therapy**

Intralesional IFN treatment involves injections of the compound into the base of each wart. For recombinant IFN- $\alpha$  2b (Intron A), injections are performed three times a week for 3 weeks, while for natural IFN- $\alpha$  (Alferon N), injections are performed two times a week for 8 weeks. For Intron, a maximum of five lesions can be treated at one session; the use of Alferon is limited by the total dose.

Controlled clinical trials have indicated that intralesional IFN therapy is more effective than placebo in clearing genital warts. In one study, 62% of pa-

**TABLE II**  
**Efficacy of Interferon in the Treatment of Genital Warts**

Route of Administration	Clearance Rates (Range)	Recurrence Rates (Range)	References
Intralesional	36-53%	21-25%	[39-41]
Topical	33%	NR	[43]
Systemic	7-82%	23%	[8, 44, 45]

NR = Not reported.

**A SYMPOSIUM: HUMAN PAPILLOMAVIRUS INFECTION/BEUTNER AND FERENCZY**

**Figure 1.** The loop electrosurgical excisional procedure (LEEP).<sup>36</sup> Removal of external HPV lesion with the use of LEEP. (A) The skin around the lesion is stretched with the nondominant hand. (B) The loop is introduced superficially slightly into the dermis. (C) The lesion is removed by drawing the loop of the probe underneath the lesion and out on the other side.

tients treated with natural IFN- $\alpha$  had complete wart clearance, compared with 21% of placebo-treated patients.<sup>30</sup> Similarly, in a trial in which recombinant IFN- $\alpha$  was injected into single warts, a clearance rate of 53% was observed, compared with 14% for placebo-treated patients.<sup>40</sup> Another trial of recombinant IFN showed a lower incidence of complete clearance of IFN-treated warts (36% vs 17% for placebo) but found that the mean wart area decreased almost 40% from initial size in IFN-treated warts compared with an increase of 46% in warts treated with placebo.<sup>41</sup> Recurrence rates of approximately 20–25% have been reported in studies that included a follow-up assessment.<sup>30,41</sup>

Although intralesional IFN therapy helps to limit IFN's systemic effects, flulike symptoms are a common side effect of this treatment. Leukopenia may occur in patients treated for  $\geq 3$  weeks. In addition, intralesional administration is a time-consuming and painful procedure.

#### **Topical Administration**

Topical creams containing IFN avoid the need for intralesional injections and have minimal side effects.<sup>42</sup> Unfortunately, results obtained with topical IFN have been disappointing. In one clinical trial, the clearance rate in IFN-treated patients approximated 35% and was not significantly different from that re-

**A SYMPOSIUM: HUMAN PAPILLOMAVIRUS INFECTION/BEUTNER AND FERENCZY**

ported in the placebo group.<sup>43</sup> Thus, current preparations of topical IFN appear to offer little benefit in the treatment of genital warts.

#### **Systemic Administration**

Systemic administration of IFN is another option for selected rare patients with genital warts. In a study in which IFN gamma (IFN- $\gamma$ ) was administered intramuscularly to 28 patients with refractory condylomata acuminata, an overall response rate of 59% was observed.<sup>44</sup> In small studies involving daily subcutaneous or intramuscular injections of IFN- $\alpha$  or IFN- $\beta$ , clearance rates of approximately 30% have been observed.<sup>45</sup> Recurrence rates have been encouragingly low in some studies,<sup>46</sup> but a larger trial found a recurrence rate of 23% and concluded that podophyllin treatment was significantly more effective than systemic IFN- $\alpha$ .<sup>8</sup>

The adverse effects associated with systemic IFN are substantial. In the small studies conducted to date, all patients experienced systemic adverse reactions.<sup>42</sup> Almost 30% of patients had to discontinue treatment due to adverse effects, and dose reductions were also common.

#### **Adjuvant Therapy With IFN**

There are some suggestions that IFN may be a valuable adjunct to conventional therapy, particularly in patients with refractory warts. Although subcutaneous IFN- $\alpha$  did not increase the efficacy of cryotherapy in one controlled trial,<sup>47</sup> another study indicated that prior systemic IFN- $\gamma$  improved responses to cryotherapy.<sup>48</sup> Similarly, systemic IFN- $\alpha$  has been reported to lower the recurrence rate in patients treated with laser therapy.<sup>49</sup>

Adjuvant therapy with intralesional IFN has also been examined. One combination that has been studied is podophyllin and intralesional IFN.<sup>9</sup> Although adjunctive IFN resulted in a higher rate of complete clearance of warts (67% compared with 42% for podophyllin alone), recurrence rates were similar between the two groups (67% and 65%, respectively). More promising results were obtained when intralesional IFN was used as an adjuvant to either laser or 5-FU therapy. In this instance, a decreased incidence of recurrent anogenital lesions was found in patients who received adjuvant IFN therapy compared with those who did not (7% vs 24%).<sup>48</sup> An independent study of subcutaneous IFN therapy following CO<sub>2</sub> laser therapy found that clearance rates were twice as high in patients receiving adjuvant IFN therapy compared with those receiving placebo.<sup>50</sup>

#### **NEW THERAPIES FOR THE TREATMENT OF EXTERNAL GENITAL WARTS**

New therapies for genital warts focus on improving delivery of therapeutic agents to genital lesions

and stimulating the immune system to combat the virus. These treatments offer exciting options to conventional treatments and may play an important role in future therapeutic decisions.

#### **5-FU/Epinephrine**

An injectable gel containing 5-FU and epinephrine in a protein carrier matrix of purified bovine collagen is being studied for use in the treatment of genital warts and some malignancies. The therapeutic compound in this formulation is 5-FU; epinephrine serves as a vasoconstrictor and acts to retain 5-FU at the site of the lesion.<sup>50</sup> This agent is thus able to maintain high local concentrations of 5-FU at the site of injection.

In a clinical trial of 401 patients with condylomata acuminata, patients received one intralesional treatment of 5-FU/epinephrine gel, 5-FU gel, or placebo per lesion once weekly for up to 6 weeks. A complete response rate of 61% occurred in the group receiving the 5-FU/epinephrine combination, compared with 43% in the group receiving 5-FU alone and 5% in the placebo group. Patients with limited disease (total lesion areas of <100 mm<sup>2</sup>) showed the best response to 5-FU/epinephrine, with a complete response rate of 71%; patients with more extensive lesions had a complete response rate of 25%. The 3-month recurrence rate in 5-FU/epinephrine-treated patients whose warts had regressed completely was 39%.<sup>51</sup>

Adverse effects of this therapy include pain during injection and local skin reactions, most notably erythema, swelling, erosions, and ulcerations. No systemic effects were observed in the clinical trial.

#### **Solid-Formulation Podofilox**

Gel and cream formulations of 0.5% podofilox have recently been tested for use in the treatment of external anogenital warts. Although the strength of podofilox is the same in the solid formulations as in the solution formulation currently available, the solid formulations are easier to apply and do not require an applicator. The treatment regimen involves application of solid-formulation podofilox twice daily for 3 consecutive days followed by a 4-day rest period. This treatment cycle is repeated until all warts are cleared or for a maximum of 8 weeks.

Although podofilox cream may be more convenient to apply than the solution formulation, its therapeutic efficacy does not appear to be improved. In a comparative study of podofilox cream versus podofilox solution in male patients with genital warts, similar clearance rates and side effects were observed in the two treatment groups.<sup>52</sup>

Podofilox gel has been compared to vehicle gel in a clinical trial, but there are as yet no published data from a comparative trial with podofilox solution. In

## A SYMPOSIUM: HUMAN PAPILLOMAVIRUS INFECTION/BEUTNER AND FERENCZY




Figure 2. Kinetics of cytokine induction by imiquimod in human peripheral blood mononuclear cells. (Adapted from *J Leukoc Biol.*<sup>57</sup>)

316 evaluable patients with anogenital warts, complete wart clearance was observed in 37% of 213 patients after four treatment cycles compared to 2% of 103 patients receiving vehicle gel.<sup>53</sup> After 8 weeks of treatment, 45% of podofilox-treated patients experienced complete wart clearance. Wart recurrence occurred in 32% of successfully treated patients, usually within the first 4 weeks following treatment.

These studies thus suggest that the efficacies of solid and solution formulations of podofilox are similar. However, the improved ease of application may make solid formulations of podofilox an attractive alternative to podofilox solution.

### Imiquimod

One immune-response modifier that has recently become the focus of much study is imiquimod. Although imiquimod has no direct antiviral activity, preclinical studies in animal models have demonstrated that imiquimod is a potent inducer of IFN- $\alpha$  and enhances cell-mediated cytolytic activity against viral targets.<sup>54,55</sup> In cell-culture studies with human blood cells, imiquimod resulted in the production of high levels of IFN- $\alpha$ .<sup>56</sup> Imiquimod also induces a variety of other cytokines in human peripheral blood mononuclear cells, including interleukin-1 (IL-1), IL-6, IL-8, tumor necrosis factor (TNF), and IFN. The induction of cytokines is rapid and sustained (Figure 2).<sup>57</sup>

Imiquimod 5% cream has been tested in patients with genital warts in five multicenter, double-blind, vehicle-controlled, clinical trials. Patients applied the cream overnight ( $8 \pm 2$  hours) three times per week. Treatment was continued for up to 16 weeks or until warts were completely cleared. After a 12-week treatment-free period, the presence of warts was assessed.

Of the 209 patients enrolled in this trial, 109 patients received imiquimod 5% cream and 100 received vehicle cream. Of the 109 patients in the im-

iquimod 5% group, 36 completed 16 weeks of treatment without totally clearing their warts, 19 withdrew during the treatment period, and 54 totally cleared their warts. Of the 54 patients in the imiquimod 5% group who totally cleared their warts in the treatment period, 39 completed the 12-week follow-up period and remained clear. The other patients were either lost to follow-up or experienced recurrences (Figure 3).

Of the 100 patients in the vehicle group, 62 completed the 16 weeks of therapy without totally clearing their warts, 27 withdrew during the treatment period, and 11 totally cleared their warts. Of the 11 patients in the vehicle group who totally cleared their warts in the treatment period, 9 completed the 12-week follow-up period and remained clear. The other patients were either lost to follow-up or experienced recurrences (Figure 3).

The patients treated with imiquimod 5% cream had clearance rates of 50% (72% of females, 33% of males), which were significantly higher than those in patients receiving vehicle cream, who had total clearance rates of 11% (20% of females, 5% of males).<sup>58</sup>

Higher clearance rates were observed in females than in males, possibly due to differences in keratinization of wart tissue.

Local skin reactions, including erythema (61%), erosion (30%), and excoriation/flaking (23%), were the most commonly reported treatment-related events. These reactions were usually mild to moderate in intensity. Overall, 1.2% (4/327) of the patients discontinued due to local skin/application-site reactions.<sup>59</sup>


These data suggest that topical imiquimod may have several advantages over conventional agents in the treatment of external genital warts. Imiquimod is easily applied by the patient and results in acceptable total clearance rates. Systemic side effects are negligible, and local effects are generally tolerable. Topical administration of imiquimod may thus be a suitable therapeutic choice for first-line treatment of external genital warts.

### PROSPECTS FOR A VACCINE

As a viral disease, HPV infection is a candidate for preventative vaccination.<sup>64</sup> A successful vaccine could potentially reduce the number of cases of HPV-associated genital cancers, particularly cervical malignancies. Current efforts are targeted at the development of prophylactic vaccines to prevent HPV disease and therapeutic vaccines that help boost the host's immune response to HPV-infected cells.

Because HPV cannot be cultured, most attention to date has been focused on the possibility of a vaccine composed of a specific HPV subunit. Such a

## A SYMPOSIUM: HUMAN PAPILLOMAVIRUS INFECTION/BEUTNER AND FERENCZY

Figure 3. Imiquimod patient accountability for Study 1004 clinical trial.<sup>58</sup>

strategy has been successfully employed in the development of a vaccine for the hepatitis B virus. Potential candidates for an immunogenic HPV subunit include the major and minor capsid proteins L1 and L2. L1, by itself or with L2, can self-assemble into virus-like particles that have a conformation similar to that of intact virions.<sup>50,50</sup> In animal model systems, immunization with these virus-like particles results in the production of antibodies capable of neutralizing the intact virus.<sup>61,62</sup> Alternatively, peptides from the E6 or E7 proteins—the HPV-transforming proteins—are a possible source of a prophylactic or therapeutic vaccine against HPV-associated malignancies.<sup>61</sup>

A potential difficulty with vaccines for genital warts is that >20 different types of HPV can cause genital lesions.<sup>63</sup> Accordingly, effective vaccination will require either the identification of a common antigenic epitope or the development of a multivalent vaccine directed against the relevant HPV types.

## CONCLUSIONS

A variety of therapies are available for the treatment of genital warts. The best choice of treatment for a given patient depends on the extent and location of disease and the preferences of the clinician and patient.

Current therapies for the treatment of genital warts probably do not eradicate the viral reservoir present in adjacent tissue. Thus, in many cases

these treatments are destined to fail, as indicated by the high rate of recurrent infections. Despite the high recurrence rates associated with current therapies, however, wart clearance is usually achieved in the majority of patients. In some cases, several therapies must be tried over a period of a few months to a year. Even when warts do recur, the patients receive some benefit from a sustained wart-free period.

There is little doubt, however, that new therapeutic options would be a welcome addition to the arsenal of treatment modalities available for genital warts. By prompting the host to join the fight against HPV infection, new immunomodulatory therapies and vaccines hold promise for increasing the success rate of treating genital warts. Improving the delivery of therapeutic compounds to the site of infection may also produce beneficial results.

None of the therapies studied to date purports to be a "cure" for HPV infection. However, with every advance in the treatment of genital warts, more is learned about this disease and the optimal method of combating it. Most importantly, these advances may translate into reduced pain and discomfort for patients with genital warts.

## REFERENCES

- Stone KM. Human papillomavirus infection and genital warts: update on epidemiology and treatment. *Clin Infect Dis*. 1995;20(suppl 1):S91-S97.
- Ferenczy A, Mitao M, Nagai N, Silverstein SJ, Crum CP. Latent papilloma virus and recurring genital warts. *N Engl J Med*. 1985;313:784-788.

**A SYMPOSIUM: HUMAN PAPILLOMAVIRUS INFECTION/BEUTNER AND FERENCYZ**

3. Abdullah AN, Walzman M, Wade A. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. *Sex Transm Dis.* 1993;20:344-345.
4. Godley MJ, Bradbeer CS, Gellan M, Thin RN. Cryotherapy compared with trichloroacetic acid in treating genital warts. *Genitourin Med.* 1987;63:390-392.
5. Centers for Disease Control and Prevention. 1993 Sexually transmitted diseases treatment guidelines: human papillomavirus infection. MMWR. 1993;42:83-88.
6. Petersen CS, Weismann K. Quercetin and kaempferol: an argument against the use of podophyllin? *Genitourin Med.* 1995;71:92-93.
7. Bashi SA. Cryotherapy versus podophyllin in the treatment of genital warts. *Int J Dermatol.* 1985;24:535-538.
8. The Condyloma International Collaborative Study Group. A comparison of interferon alfa-2a and podophyllin in the treatment of primary condylomata acuminata. *Genitourin Med.* 1991;67:394-399.
9. Douglas JM Jr, Eron LJ, Judson FN, et al. A randomized trial of combination therapy with intralesional interferon  $\alpha_2a$  and podophyllin versus podophyllin alone for the therapy of anogenital warts. *J Infect Dis.* 1990;162:52-59.
10. Khawaja HT. Podophyllin versus scissor excision in the treatment of perianal condylomata acuminata: a prospective study. *Br J Surg.* 1989;76:1067-1068.
11. Stone KM, Becker TM, Hadgu A, Kraus SJ. Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodeicculation. *Genitourin Med.* 1990;66:16-19.
12. Mazurkiewicz W, Jablonska S. Comparison between the therapeutic efficacy of 0.5% podophyllotoxin preparations and 20% podophyllin ethanol solution in condylomata acuminata. *Z Hautkr.* 1986;61:1387-1395.
13. Jensen SL. Comparison of podophyllin application with simple surgical excision in clearance and recurrence of perianal condylomata acuminata. *Lancet.* 1985;i:1146-1148.
14. Edwards A, Alme-Ram A, Thin RN. Podophyllotoxin 0.5% v podophyllin 20% to treat penile warts. *Genitourin Med.* 1988;64:263-265.
15. Fisher AA. Severe systemic and local reactions to topical podophyllum resin. *Cancer.* 1981;28:233-266.
16. Eron LJ. Human papillomaviruses and anogenital disease. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. *Infectious Diseases*. Philadelphia: WB Saunders, 1992:852-856.
17. Baumler KR. Podophyllotoxin in the treatment of genital human papillomavirus infection: a review. *Semin Dermatol.* 1987;6:10-18.
18. Beutner KR, Conant MA, Friedman-Kien AE, et al. Patient-applied podofilox for treatment of genital warts. *Lancet.* 1989;i:831-834.
19. Greenberg MD, Rutledge LH, Reid R, Berman NR, Precop SL, Elswick RK Jr. A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. *Obstet Gynecol.* 1991;77:735-739.
20. Pride GL. Treatment of large lower genital tract condylomata acuminata with topical 5-fluorouracil. *J Reprod Med.* 1990;35:384-387.
21. Ferencyz A. Comparison of 5-fluorouracil and CO<sub>2</sub> laser for treatment of vaginal condylomata. *Obstet Gynecol.* 1984;64:773-778.
22. Krebs HB. The use of topical 5-fluorouracil in the treatment of genital condylomas. *Obstet Gynecol Clin North Am.* 1987;14:559-568.
23. Ferencyz A. Epidemiology and clinical pathophysiology of condylomata acuminata. *Am J Obstet Gynecol.* 1995;172:1331-1339.
24. Goodman A, Zukerberg LR, Nikrui N, Scully RE. Vaginal adenosis and clear cell carcinoma after 5-fluorouracil treatment for condylomas. *Cancer.* 1991;68:1628-1632.
25. Ferencyz A. Topical 5-fluorouracil cream (Efudex) has a role in the treatment of HPV-related genital lesions. *Contemp Obstet Gynecol.* 1997; in press.
26. Damstra RJ, van Vloten WA. Cryotherapy in the treatment of condylomata acuminata: a controlled study of 64 patients. *J Dermatol Surg Oncol.* 1991;17:273-276.
27. Bergman A, Bhatia NN, Broen EM. Cryotherapy for treatment of genital condylomata during pregnancy. *J Reprod Med.* 1984;29:432-435.
28. Baggish MS. Carbon dioxide laser treatment for condylomata acuminata: venereal infections. *Obstet Gynecol.* 1980;55:711-715.
29. Calkins JV, Masterson BJ, Magrina JF, Capen CV. Management of condylomata acuminata with the carbon dioxide laser. *Obstet Gynecol.* 1982;59:105-108.
30. Ferencyz A. Laser therapy of genital condylomata acuminata. *Obstet Gynecol.* 1984;63:703-707.
31. Ferencyz A, Behelak Y, Haber G, Wright TC Jr, Richart RM. Treating vaginal and external anogenital condylomas with electrosurgery vs CO<sub>2</sub> laser ablation. *J Gynecol Surg.* 1995;11:41-50.
32. Ferencyz A. Treating genital condyloma during pregnancy with the carbon dioxide laser. *Am J Obstet Gynecol.* 1984;148:9-12.
33. Ferencyz A, Bergeron C, Richart RM. Human papillomavirus DNA in CO<sub>2</sub> laser-generated plume of smoke and its consequences to the surgeon. *Obstet Gynecol.* 1990;76:114-118.
34. Ferencyz A, Bergeron C, Richart RM. Carbon dioxide laser energy disperses human papillomavirus deoxyribonucleic acid onto treatment fields. *Am J Obstet Gynecol.* 1990;163:1271-1274.
35. Ferencyz A, Choukroun D, Arsenau J. Loop electrosurgical excision procedure for squamous intraepithelial lesions of the cervix: advantages and potential pitfalls. *Obstet Gynecol.* 1996;87:332-337.
36. Mayeaux EJ Jr, Harper MB, Barksdale W, Pope JB. Noncervical human papillomavirus genital infections. *Am Fam Physician.* 1995;52:1137-1146.
37. Mathevet P, Dargent D, Roy M, Beau G. A randomized prospective study comparing three techniques of conization: cold knife, laser, and LEEP. *Gynecol Oncol.* 1994;54:175-179.
38. Reichman RC, Oakes D, Bonnez W, et al. Treatment of condyloma acuminatum with three different interferon- $\alpha$  preparations administered parenterally: a double-blind, placebo-controlled trial. *J Infect Dis.* 1990;162:1270-1276.
39. Friedman-Kien AE, Eron LJ, Conant M, et al. Natural interferon alfa for treatment of condylomata acuminata. *JAMA.* 1988;259:533-538.
40. Vance JC, Bart BJ, Hansen RC, et al. Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. *Arch Dermatol.* 1986;122:272-277.
41. Eron LJ, Judson F, Tucker S, et al. Interferon therapy for condylomata acuminata. *N Engl J Med.* 1986;315:1059-1064.
42. Kraus SJ, Stone KM. Management of genital infection caused by human papillomavirus. *Rev Infect Dis.* 1990;12(suppl 6):S620-S632.
43. Keay S, Teng N, Eisenberg M, Story B, Sellers PW, Merigan TC. Topical interferon for treating condyloma acuminata in women. *J Infect Dis.* 1988;158:934-939.
44. Kirby PK, Kiviat N, Beckman A, Wells D, Sherwin S, Corey L. Tolerance and efficacy of recombinant human interferon gamma in the treatment of refractory genital warts. *Am J Med.* 1988;85:183-188.
45. Schonfeld A, Nitke S, Schattner A, et al. Intramuscular human interferon- $\beta$  injections in treatment of condylomata acuminata. *Lancet.* 1984;i:1038-1042.
46. Handley JM, Horner T, Maw RD, Lawther H, Dinsmore WW. Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised observer blind placebo controlled study. *Genitourin Med.* 1991;67:297-302.
47. Gross G, Roussaki A, Baur S, Wiegand M, Mescheder A. Systemically administered interferon alfa-2a prevents recurrence of condylomata acuminata following CO<sub>2</sub> laser ablation. The influence of the cyclic low-dose therapy regimen. Results of a multicentre double-blind placebo-controlled trial. (Letter.) *Genitourin Med.* 1996;72:71.
48. Kutika JJ, Bergman A. Interferon as an adjuvant treatment for genital condyloma acuminatum. *Int J Gynaecol Obstet.* 1995;49:171-174.
49. Petersen CS, Bjerring P, Larsen J, et al. Systemic interferon alpha-2b Increases the cure rate in laser treated patients with multiple persistent genital warts: a placebo-controlled study. *Genitourin Med.* 1991;67:99-102.
50. Wolf W, Wulch V, Kim H, et al. Noninvasive <sup>19</sup>F-magnetic resonance spectroscopy to evaluate tumor pharmacokinetics of AccuSite™ (fluorouracil/epinephrine) injectable gel for treatment of human basal cell carcinoma. *Proc Ann Meet Am Assoc Cancer Res.* 1995;36:A2174.
51. Human Papillomaviruses: Infectious Disease Study #19. Waltham, MA: Decision Resources, 1995:49-50.
52. Petersen CS, Agner T, Ottevanger V, Larsen J, Ravnborg L. A single-blind study of podophyllotoxin cream 0.5% and podophyllotoxin solution 0.5% in male patients with genital warts. *Genitourin Med.* 1995;71:391-392.

**A SYMPOSIUM: HUMAN PAPILLOMAVIRUS INFECTION/BEUTNER AND FERENCZY**

53. Tying SK, Edwards LE, Ramsdell WM, et al. A double-blind comparison of 0.5% podoflox gel and vehicle gel in the treatment of external anogenital warts. Presented at the American Academy of Dermatology Conference, February 10-15, 1996, Washington, DC.

54. Coleman N, Birley HDL, Renton AM, et al. Immunological events in regressing genital warts. *Am J Clin Pathol.* 1994;102:768-774.

55. Harrison CJ, Jenski L, Voychekovski T, Bernstein DI. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. *Antiviral Res.* 1988;10:209-224.

56. Weeks CE, Gibson SJ. Alpha interferon induction in human blood cell culture by immunomodulator candidate R-837. *J Interferon Res.* 1989;9(suppl 2):S215.

57. Testerman TL, Gerster JF, Imbertson LM, et al. Cytokine induction by the immunomodulators imiquimod and S-27609. *J Leukoc Biol.* 1995;58:365-372.

58. Full prescribing information for Aldara® (Imiquimod) Cream, 5%, March 1997.

59. Krbnauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. *J Virol.* 1993;67:6929-6936.

60. Hines JF, Ghim SJ, Christensen ND, et al. Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination. *Gynecol Oncol.* 1994;55:13-20.

61. Lowy DR, Krbnauer R, Schiller JT. Genital human papillomavirus infection. *Proc Natl Acad Sci USA.* 1994;91:2436-2440.

62. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. *J Virol.* 1996;70:960-965.

63. de Villiers E-M. Heterogeneity of the human papillomavirus group. *J Virol.* 1989;63:4898-4903.